Photo by polarmermaid from unsplash
A randomized phase II trial reports the clinical efficacy of poly(ADPribose) polymerase (PARP) inhibitor olaparib combined with abiraterone in metastatic castrationresistant prostate cancer. At a cutoff date in September 2017,… Click to show full abstract
A randomized phase II trial reports the clinical efficacy of poly(ADPribose) polymerase (PARP) inhibitor olaparib combined with abiraterone in metastatic castrationresistant prostate cancer. At a cutoff date in September 2017, median radiographic progressionfree survival was significantly longer in the abiraterone plus olaparib group than in the abiraterone plus placebo group (13.8 versus 8.2 months; HR 0.65, 95% CI 0.44–0.97, P = 0.034). Regarding safety, patients receiving the combination therapy had more grade 3 or worse and serious adverse events than those in the placebo arm.
Journal Title: Nature Reviews Urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!